Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
62,457,444
-
Total 13F shares
-
70,684,460
-
Share change
-
-284,334
-
Total reported value
-
$4,695,410,423
-
Put/Call ratio
-
30%
-
Price per share
-
$66.43
-
Number of holders
-
274
-
Value change
-
+$4,458,380
-
Number of buys
-
122
-
Number of sells
-
148
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, $0.00001 par value (PTGX) as of Q3 2025
As of 30 Sep 2025,
Protagonist Therapeutics, Inc - Common Stock, $0.00001 par value (PTGX) was held by
274 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,684,460 shares.
The largest 10 holders included
BlackRock, Inc., FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, VANGUARD GROUP INC, STATE STREET CORP, BVF INC/IL, JOHNSON & JOHNSON, WELLINGTON MANAGEMENT GROUP LLP, UBS Group AG, and Deep Track Capital, LP.
This page lists
274
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.